Agelink, MW, Majewski, T., Wurthmann, C., Lukas, K., Ullrich, H., Linka, T., et al. (2001) Effects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole and clozapine. J Clin Psychopharmacol21: 8-13.
2.
American Psychiatric Association (2004) Practice Guidelines for the Treatment of Patients with Schizophrenia, second ed. http://www.psychiatryonline.com/pracGuide/pracGuideTopic_6.aspx (accessed 22.03.08).
3.
De Bruin, ML, Pettersson, M., Meyboom, RHB, Hoes, AW, Leufkens, HGM ( 2005) Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. Eur Heart J26: 590-597.
4.
European Medicines Agency (2005) Committee for Proprietary Medicinal Products. The Non-Clinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals. Note for Guidance on the Non-Clinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals. http://www.emea.europa.eu/pdfs/human/ich/042302en.pdf (accessed 22.03.08).
5.
Gil, FP, Grohmann, R., Ruther, E. ( 2001) Asymptomatic bradycardia associated with amisulpride . Pharmacopsychiatry34: 259-261.
6.
Gupta, A., Lawrence, AT, Krishnan, K., Kavinsky, CJ, Trohman, RG ( 2007) Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. Am Heart J153: 891-899.
7.
Isbister, GK, Murray, L., John, S., Hackett, LP, Haider, T., O’Mullane, P., et al. (2006) Amisulpride deliberate self-poisoning causing severe cardiac toxicity including QT prolongation and torsade de pointes. Med J Aust184: 354-356.
8.
Kongsamut, S., Kang, J., Chen, XL, Roehr, J., Rampe, D. ( 2002) A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. Eur J Pharm450: 37-41.
9.
Lynch, MJ, Woods, J., George, N., Gerostamoulos, D. ( 2008) Fatality due to amisulpride toxicity: a case report . Med Sci Law48: 173- 177.
10.
Mago, R. ( 2004) Searching the medical literature for case reports . J Clin Psychiatry65: 444-445.
11.
Naranjo, CA, Busto, U., Sellers, EM, Sandor, P., Ruiz, I., Roberts, EA, et al. (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther30: 239-245.
12.
National Institute of Clinical Excellence ( 2002) Guidance on the Use of Newer (atypical) Antipsychotic Drugs for the Treatment of Schizophrenia. http://www.nice.org.uk/guidance/index.jsp?action=download&o=32378 (accessed 22.03.08).
13.
Sanofi-Aventis (2007) Solian (Amisulpride) Product Insert: Sanofi-Aventis. Hong Kong Limited.
14.
Titier, K., Canal, M., Deridet, E., Abouelfath, A., Gromb, S., Molimard, M., et al. (2004) Determination of myocardium to plasma concentration ratios of five antipsychotic drugs: comparison with their ability to induce arrhythmia and sudden death in clinical practice. Toxicol Appl Pharmacol199: 52-60.
15.
Titier, K., Girodet, P., Verdoux, H., Molimard, M., Begaud, B., Haverkamp, W., et al. (2005) Atypical antipsychotics from potassium channels to torsade de pointes and sudden death. Drug Saf28: 35-51.
16.
Tracqui, A., Mutter-Schmidt, C., Kintz, P., Berton, C., Mangin, P. ( 1995) Amisulpride poisoning: a report of two cases. Hum Exp Toxicol14: 294-298.
17.
Ward, DI ( 2005) Two cases of amisulpride overdose: a cause for prolonged QT syndrome. Emerg Med Australas17: 274-276.
